Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways

Neuropsychopharmacology

Volumn 32, Issue 1, 2007, Pages 67-77

  Urban, Jonathan D ^a   Vargas, Gabriel A ^b   Von Zastrow, Mark ^b,c   Mailman, Richard B ^a,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Aripiprazole; Atypical antipsychotic drugs; D2 dopamine receptors; Functional selectivity; Partial agonism

Indexed keywords

AMISULPRIDE; ARACHIDONIC ACID; ARIPIPRAZOLE; CLOZAPINE; CYCLIC AMP; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR STIMULATING AGENT; GUANOSINE TRIPHOSPHATE; HALOPERIDOL; MELPERONE; MITOGEN ACTIVATED PROTEIN KINASE; OLANZAPINE; QUINPIROLE;

ANIMAL CELL; ARTICLE; COMPREHENSION; DRUG ACTIVATION; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RELEASE; EMBRYO; ENZYME PHOSPHORYLATION; FEMALE; HAMSTER; HUMAN; HUMAN CELL; HYPOTHESIS; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; STATISTICAL SIGNIFICANCE;

ANALYSIS OF VARIANCE; ANIMALS; ARACHIDONIC ACID; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; CYCLIC AMP; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; ENZYME-LINKED IMMUNOSORBENT ASSAY; GUANOSINE TRIPHOSPHATE; MITOGEN-ACTIVATED PROTEIN KINASES; PIPERAZINES; QUINOLONES; QUINPIROLE; RECEPTORS, DOPAMINE D2; SIGNAL TRANSDUCTION;

EID: 33845718611     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301071     Document Type: Article

References (60)

1. Allouche S, Polastron J, Hasbi A, Homburger V, Jauzac P (1999). Differential G-protein activation by alkaloid and peptide opioid agonists in the human neuroblastoma cell line SK-N-BE. Biochem J 342(Part 1): 71-78.
2. Berg KA, Maayani S, Clarke WP (1996). 5-Hydroxytryptamine2c receptor activation inhibits 5-hydroxytryptamine1B-like receptor function via arachidonic acid metabolism. Mol Pharmacol 50: 1017-1023.
3. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, Clarke WP (1998). Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54: 94-104.
4. Berry SA, Shah MC, Khan N, Roth BL (1996). Rapid agonist-induced internalization of the 5-hydroxytryptamine2A receptor occurs via the endosome pathway in vitro. Mol Pharmacol 50: 306-313.
5. Bolonna AA, Kerwin RW (2005). Partial agonism and schizophrenia. Br J Psychiatry 186: 7-10.
6. Brink CB, Wade SM, Neubig RR (2000). Agonist-directed trafficking of porcine alpha(2A)-adrenergic receptor signaling in Chinese hamster ovary cells: l-isoproterenol selectively activates G(s). J Pharmacol Exp Ther 294: 539-547.
7. 2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol 534: 63-70.
8. 2 receptors. J Pharmacol Exp Ther 302: 381-389.
9. Carlsson A (1964). Evidence for a role of dopamine in extrapyramidal functions. Acta Neuroveg (Wien) 26: 484-493.
10. 2 isoforms: a perspective. Cell Signal 15: 637-665.
11. 50) of an enzymatic reaction. Biochem Pharmacol 22: 3099-3108.
12. 2 receptors. Biochem Biophys Res Commun 256: 33-40.
13. Clark D, Carlsson A, Hjorth S, Svensson K, Engel J, Sanchez D (1982). Is 3-PPP a potential antipsychotic agent? Evidence from animal behavioral studies. Eur J Pharmacol 83: 131-134.
14. Davies MA, Sheffler DJ, Roth BL (2004). Aripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 10: 317-336.
15. Felder CC, Williams HL, Axelrod J (1991). A transduction pathway associated with receptors coupled to the inhibitory guanine nucleotide binding protein Gi that amplifies ATP-mediated arachidonic acid release. Proc Natl Acad Sci USA 88: 6477-6480.
16. Ferguson SS (2001). Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 53: 1-24.
17. 2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol 66: 97-105.
18. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR et al (2001). Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276: 24433-24436.
19. 2 receptors. Mol Pharmacol 56: 1362-1369.
20. 2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27: 1081-1090.
21. 2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50: 873-883.
22. 2 receptor antagonistic activity. J Pharmacol Exp Ther 274: 329-336.
23. Kilts JD, Connery HS, Arrington EG, Lewis MM, Lawler CP, Oxford GS et al (2002). Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs. J Pharmacol Exp Ther 301: 1179-1189.
24. 3 receptors by G protein-coupled receptor kinases and beta-arrestins. J Biol Chem 276: 37409-37414.
25. Kukkonen JP, Jansson CC, Akerman KE (2001). Agonist trafficking of G(i/o)-mediated alpha(2A)-adrenoceptor responses in HEL 92.1.7 cells. Br J Pharmacol 132: 1477-1484.
26. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, Nichols DE (2003). Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304: 229-237.
27. Lahti AC, Weiler MA, Corey PK, Lahti RA, Carlsson A, Tamminga CA (1998). Antipsychotic properties of the partial dopamine agonist (-)-3-(3-hydroxyphenyl) -N-n-propylpiperidine(preclamol) in schizophrenia. Biol Psychiatry 43: 2-11.
28. Lavoie C, Hebert TE (2003). Pharmacological characterization of putative beta1-beta2-adrenergic receptor heterodimers. Can J Physiol Pharmacol 81: 186-195.
29. Lawler CP, Prioleau C, Lewis MM, Mak C, Jiang D, Schetz JA et al (1999). Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20: 612-627.
30. Lefkowitz RJ, Limbird LE, Williams LT, Wessels M (1978). Beta-adrenergic receptors: regulatory role of agonists. J Supramol Struct 8: 501-510.
31. Levine L, Moskowitz MA (1979). Alpha- and beta-adrenergic stimulation of arachidonic acid metabolism in cells in culture. Proc Natl Acad Sci USA 76: 6632-6636.
32. 1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J Pharmacol Exp Therap 286: 345-353.
33. Lieberman JA (2004). Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 18: 251-267.
34. 2L glioma cells. J Neurochem 71: 980-990.
35. 2 dopamine receptors (a lesson for drug discovery). Med Chem Res 13: 115-126.
36. Maudsley S, Martin B, Luttrell LM (2005). The origins of diversity and specificity in g protein-coupled receptor signaling. J Pharmacol Exp Ther 314: 485-494.
37. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998). Dopamine receptors: from structure to function. Physiol Rev 78: 189-225.
38. Miyamoto S, Duncan GE, Mailman RB, Lieberman JA (2000). Developing novel antipsychotic drugs: strategies and goals. Curr Opin CPNS Invest Drugs 2: 25-39.
39. 2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301: 1166-1178.
40. 2 receptor synergism. Nature 353: 164-167.
41. Reversi A, Rimoldi V, Marrocco T, Cassoni P, Bussolati G, Parenti M et al (2005). The oxytocin receptor antagonist atosiban inhibits cell growth via a 'biased agonist mechanism'. J Biol Chem 280: 16311-16318.
42. Roettger BF, Ghanekar D, Rao R, Toledo C, Yingling J, Pinon D et al (1997). Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor. Mol Pharmacol 51: 357-362.
43. Roth RH (1979). Dopamine autoreceptors: pharmacology, function and comparison with post-synaptic dopamine receptors. Commun Psychopharmacol 3: 429-445.
44. 1 receptor agonists. Mol Pharmacol 68: 1039-1048.
45. Shapiro DA, Renock S, Arrington E, Sibley DR, Chiodo LA, Roth BL et al (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28: 1400-1411.
46. Simmons MA (2005). Functional selectivity, ligand-directed trafficking, conformation-specific agonism: What's in a name? Mol Interv 5: 154-157.
47. Stahl SM (2001). Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J Clin Psychiatry 62: 923-924.
48. Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T et al (2005). Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 515: 10-19.
49. Tamminga CA (2002). Partial dopamine agonists in the treatment of psychosis. J Neural Transm 109: 411-420.
50. Tamminga CA, Cascella NG, Lahti RA, Lindberg M, Carlsson A (1992). Pharmacologic properties of (-)-3PPP (preclamol) in man. J Neural Transm Gen Sect 88: 165-175.
51. Tamminga CA, Gotts MD, Thaker GK, Alphs LD, Foster NL (1986). Dopamine agonist treatment of schizophrenia with N-propylnorapomorphine. Arch Gen Psychiatry 43: 398-402.
52. Tamminga CA, Schaffer MH, Smith RC, Davis JM (1978). Schizophrenic symptoms improve with apomorphine. Science 200: 567-568.
53. 3 receptor signaling in Chinese hamster ovary cells. Psychopharmacology (Berlin) 150: 383-390.
54. 1 dopamine receptor. J Biol Chem 279: 37461-37469.
55. Versteeg HH, Nijhuis E, van den Brink GR, Evertzen M, Pynaert GN, van Deventer SJ et al (2000). A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. Biochem J 350(Part 3): 717-722.
56. Vickery RG, von Zastrow M (1999). Distinct dynamin-dependent and -independent mechanisms target structurally homologous dopamine receptors to different endocytic membranes. J Cell Biol 144: 31-43.
57. von Zastrow M (2003). Mechanisms regulating membrane trafficking of G protein-coupled receptors in the endocytic pathway. Life Sci 74: 217-224.
58. 1 dopamine receptor agonists. Synapse 21: 177-187.
59. 2 dopamine receptor that adopts the activated conformation. J Neurochem 77: 493-504.
60. 2 phosphorylation and arachadonic acid release in primary murine astrocytes. J Neurochem 83: 259-270.